Director/PDMR Share Dealings

Director/PDMR Share Dealings July 29, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that, followingthe appointment of Mark Enyedy as Head of Corporate Development on May 1, 2014,Mr Enyedy, a Person Discharging Managerial Responsibility, was awarded adeferred share award over 1,452 American Depositary Shares ("ADSs") (the"Award"). The Award was granted on July 28, 2014. One ADS is equal to threeShire ordinary shares of 5 pence each. The Award will normally vest, subject to continued employment, in two tranches;50% on May 1, 2016 and 50% on May 1, 2017. No consideration was paid for thegrant of the Award. This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a)of the Disclosure Rules and Transparency Rules. Tony GuthrieDeputy Company Secretary For further information please contact: Investor Relations Jeff Poulton [email protected] +1 781 482 0945 Sarah Elton-Farr [email protected] +44 1256 894157 NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We focus on providing treatments in Neuroscience, Rare Diseases,Gastrointestinal, and Internal Medicine and we are developing treatments forsymptomatic conditions treated by specialist physicians in other targetedtherapeutic areas, such as Ophthalmology. www.shire.com Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX Press Release www.shire.com